HUMALOG MIX 50 KwikPen
BIOPHARM
Identification
- Active ingredient (INN)
- INSULINE LISPRO 50% / INSULINE LISPRO PROTAMINE 50%
- Internal code
- 14 B 339
- Country of Origin
- Algeria
- Pharmaceutical form
- SC Injectable Solution (Pre-filled Pen)
- Prescription List
- Regulated (List II)
- Packaging
- boite de 05 stylos preremplis de 3ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Associated Conditions
Diabetes ketoacidosis Lactation Blindness Alcohol consumption
Long-term diabetes Insulin-dependent diabetes Pregnancy Hypopituitarism Hypothyroidism Coronary heart failure Hepatic impairment Renal impairment Surreal impairment Interchangeability Psychiatric illness Vegetative neuropathy Infant under 2 years of age Endocrine pathology Intercurrent Pathology Patients treated with pioglitazone Patients treated with animal insulin relays Weight (variation) Proliferating diabetic retinopathy Sports Carotid stenosis Elderly Subject exercising physical activity.
Mechanism of Action
Insulin glargine
Mechanism of action Insulin glargine is a weakly soluble human insulin analogue at neutral pH, totally soluble at acid pH.
After injection into the subcutaneous tissue, the acid solution is neutralized, resulting in the formation of microprecipities from which small amounts of insulin glargine are released continuously.
As a result, the concentration/time curve is regular, without peaks, predictable, and the duration of action is prolonged.
The main effect of insulin, including insulin glargine, is to regulate glucose metabolism.
Insulin and its analogues decrease blood glucose by stimulating peripheral glucose uptake, particularly in skeletal muscles and adipose tissue, and by inhibiting hepatic glucose production.
Insulin inhibits lipolysis in adipocyte, inhibits proteolysis and stimulates protein synthesis.
Clinical pharmacology studies have shown that identical doses of insulin glargine and human insulin, administered by the intravenous route of action, can affect all other insulin parameters.
Adverse Effects
- Hypoglycaemia (Very common)
- Hypernatraemia Lipohypertrophy (Common)
- Lipoatrophy (Uncommon)
- Rash Urticaria Skin reaction Hypersensitivity (Rare)
- Immediate hypersensitivity (Rare)
- Oedema of Quincke Injection site reaction (Common)
- Injection site edema (Rare)
- Skin amyloidosis at the injection site
- Inflammation at the injection site Erythema at the injection site Pruritus at the injection site
- Pain at injection site Lipodystrophy at injection site Injection site swelling Urticaria at injection site
- Visual defects (Rare)
- Retinopathy (Rare)
- Amaurose Diabetic retinopathy (complication)
- Crystall alteration Dysgueusia (Very rare)
- Hypotension Shock Muscle pain (Very rare)
- Neurological disorder Bronchospasm Adrenergic effect.